Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.38 |
| ▸ | FURIN | P09958 | 5/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.36 |
| ▸ | NPY1R | P25929 | 2/20 | 0.35 |
| ▸ | NPY4R | P50391 | 2/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | NMT2 | O60551 | 1/20 | 0.35 |
| ▸ | NMT1 | P30419 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29308956 | 0.92 | NPY5R (0.40) | FAPPTGS1PTGS2NPY1RNPY4R | |
| SCHEMBL13078356 | 0.91 | NPY5R (0.38) | FAPFURINPTGS1PTGS2NPY1R | |
| SCHEMBL20887736 | 0.91 | FAP (0.37) | FAPFURINPTGS1PTGS2NPY1R | |
| SCHEMBL16925642 | 0.91 | C3AR1 (0.40) | FAPFURINPTGS1PTGS2NPY1R | |
| SCHEMBL23420959 | 0.91 | FAP (0.37) | FAPFURINPTGS1PTGS2NPY1R | |
| SCHEMBL23256221 | 0.91 | NPY5R (0.38) | FAPFURINPTGS1PTGS2NPY1R | |
| SCHEMBL19257624 | 0.91 | NPY5R (0.38) | FAPFURINPTGS1PTGS2NPY1R | |
| SCHEMBL22134344 | 0.91 | C3AR1 (0.40) | FAPFURINPTGS1PTGS2NPY1R | |
| SCHEMBL2801888 | 0.91 | C3AR1 (0.40) | FAPFURINPTGS1PTGS2NPY1R | |
| SCHEMBL28051813 | 0.91 | C3AR1 (0.40) | FAPFURINPTGS1PTGS2NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250064954-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2025-02-27 | — | — | US | disclosed |
| US-20240342299-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMA (US) | 2024-10-17 | — | — | US | disclosed |
| US-12070506-B2 | Steroids and antibody-conjugates thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20230079407-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. | 2023-03-16 | — | — | US | disclosed |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240342299-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | FAP 2921/4885FURIN 2386/4885PRSS1 1153/4885 |
| US-12070506-B2 | Steroids and antibody-conjugates thereof | SERPINA6, NR3C1, NR3C2 | FAP 2921/4885FURIN 2386/4885PRSS1 1153/4885 |
| US-20230079407-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | CD47, MSR1, LDLR | FAP 4480/4885FURIN 2044/4885PRSS1 1064/4885 |
| US-20250064954-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | FAP 2921/4885FURIN 2386/4885PRSS1 1153/4885 |
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | FAP 4480/4885FURIN 2044/4885PRSS1 1064/4885 |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | FAP 4480/4885FURIN 2044/4885PRSS1 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.